BUZZ - TD Synnex shares fall after agreeing to acquire BlueStar
路透社2026/10/07 15:56October 7th – Technology distributor TD Synnex Corporation (SNX.N) shares fell 2.2%, closing at $272.49. SNX agreed to acquire BlueStar to expand its technology product line; specific terms were not disclosed. BlueStar is a specialized technology distributor with expertise in Automatic Identification and Data Capture (AIDC), Radio Frequency Identification (RFID), mobile technologies, and Point-of-Sale (POS) technologies. The company stated that the transaction is expected to offer SNX customers and suppliers a broader portfolio of technology products, resources, and expertise. SNX said that prior to the completion of the transaction, both SNX and BlueStar will continue to operate independently, depending on regulatory approval. Including today’s move, SNX shares have gained 81.4% year-to-date. (For the convenience of non-English speakers, Reuters offers automated translations of its reports into several languages. Automated translation may contain inaccuracies or lack desired context and is provided solely for reader convenience. Reuters accepts no responsibility for any damage or loss caused by the use of automated translation.)
October 7 - ** Technology distributor TD Synnex Corporation (SNX.N) shares fell 2.2% to close at $272.49
** SNX (link) agreed to acquire BlueStar to expand its technology portfolio; specific terms were not disclosed
** BlueStar is a specialized technology distributor with expertise in automatic identification and data capture (AIDC), radio-frequency identification (RFID), mobile technologies, and point-of-sale (POS) technologies
** The company stated that the transaction is expected to allow SNX's customers and suppliers to access a broader range of technology products, resources, and expertise
** SNX said that until the deal is completed, the company and BlueStar will continue to operate independently, pending regulatory approval
** Including today's movement, SNX's cumulative gain so far this year is 81.4%
(For the convenience of non-native English speakers, Reuters has automated the translation of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of the automated translation. The automated translation is provided for readers’ convenience only. Reuters accepts no responsibility for any harm or loss arising from use of the automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
